Alvotech and STADA Extend their Strategic Partnership Covering AVT03 (Biosimilar, Denosumab)
Shots:
- Alvotech & STADA expand their strategic collaboration covering AVT03, biosimilar of Prolia/Xgeva (denosumab), to treat osteoporosis & cancer-related bone loss, respectively
- As per the agreement, AVT03 will be developed & manufactured by Alvotech at its state-of-the-art facility while STADA becomes marketing authorization holder with semi-exclusive commercial rights across the EU, incl. Switzerland & the UK and exclusive rights in certain countries across Central Asia & the Middle East
- Furthermore, STADA gets commercial rights to the biosimilars of Humira & Stelara across Commonwealth of Independent States (CIS) countries in Central Asia while Alvotech reclaims commercial rights of AVT06, biosimilar of Eylea, from STADA
Ref: Alvotech | Image: Alvotech
Related News:- Alvotech Collaborates with Dr. Reddy’s to Commercialize AVT03 (Biosimilar, Prolia & Xgeva)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
